We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

66 hedge funds and large institutions have $130M invested in Palvella Therapeutics in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 5

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

35% more funds holding

Funds holding: 49 → 66 (+17)

14% more capital invested

Capital invested by funds: $114M → $130M (+$16.3M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 0.65% → 0.64% (-0.02%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $95K

Holders
66
Holders Change
+17
Holders Change %
+34.69%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
17
Reduced
10
Closed
5
Calls
–
Puts
$95K
Net Calls
-$95K
Net Calls Change
-$95K

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$1.5M
2
BIM
Bogle Investment Management
Massachusetts
+$1.15M
3
Millennium Management
Millennium Management
New York
+$1.1M
4
Cerity Partners
Cerity Partners
New York
+$856K
5
JP Morgan Chase
JP Morgan Chase
New York
+$545K

Top Sellers

1
LOAMU
Lombard Odier Asset Management (USA)
New York
-$3.66M
2
BI
BVF Inc
California
-$2.7M
3
OFM
Omega Fund Management
Massachusetts
-$871K
4
IBT
International Biotechnology Trust
United Kingdom
-$712K
5
SFM
Sphera Funds Management
Israel
-$534K
Name Holding Trade Value Shares
Change 		Change in
Stake
AQR Capital Management
26
AQR Capital Management
Connecticut
$417K +$387K +906 New
Creative Planning
27
Creative Planning
Kansas
$380K +$5.12K +12 +1%
Mariner
28
Mariner
Kansas
$374K +$347K +813 New
Deutsche Bank
29
Deutsche Bank
Germany
$359K +$124K +291 +59%
TA
30
Teachers Advisors
New York
$351K – – –
Charles Schwab
31
Charles Schwab
California
$332K – – –
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$309K -$38K -89 -12%
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$216K +$5.98K +14 +3%
PAM
34
Panagora Asset Management
Massachusetts
$214K – – –
Barclays
35
Barclays
United Kingdom
$205K +$189K +443 New
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$190K +$91.4K +214 +108%
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$177K -$5.55K -13 -3%
VF
38
Virtu Financial
New York
$169K +$156K +366 New
RC
39
RBF Capital
California
$155K – – –
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$150K – – –
WJA
41
Williams Jones & Associates
New York
$138K +$128K +300 New
AIG
42
American International Group
New York
$133K +$9.39K +22 +8%
CS
43
Credit Suisse
Switzerland
$133K +$67.5K +158 +121%
RJA
44
Raymond James & Associates
Florida
$116K +$27.8K +65 +35%
VOYA Investment Management
45
VOYA Investment Management
Georgia
$113K – – –
NFA
46
Nationwide Fund Advisors
Ohio
$111K – – –
Wells Fargo
47
Wells Fargo
California
$105K +$96.9K +227 New
MWNA
48
Marshall Wace North America
New York
$103K +$91.4K +214 New
Bank of America
49
Bank of America
North Carolina
$84K -$10.2K -24 -12%
FLPIM
50
F.L. Putnam Investment Management
Massachusetts
$77K +$70.9K +166 New
1
2
3

PVLA Hedge Fund Activity: Q3 2017 in Review

66 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2017, worth a combined $130M — up 14% from $114M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new PVLA positions and 5 closed out — a net gain of 17 holders — while 17 added to existing stakes and 10 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.5M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $3.66M.

  • 66 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2017, up from 49 in Q2 2017.
  • Funds reported $130M of Palvella Therapeutics stock for Q3 2017, up 14% quarter-over-quarter.
  • 22 funds opened new Palvella Therapeutics positions in Q3 2017 and 5 closed out, a net change of +17 holders.
  • The largest Palvella Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $1.5M added.
  • The largest Palvella Therapeutics seller in Q3 2017 was Lombard Odier Asset Management (USA), an estimated $3.66M sold.

Based on aggregated 13F filings for Q3 2017.